Literature DB >> 11903057

Comparative characterization of two DEAD-box RNA helicases in superfamily II: human translation-initiation factor 4A and hepatitis C virus non-structural protein 3 (NS3) helicase.

Mark X Du1, Robert B Johnson, Xin-Lai Sun, Kirk A Staschke, Joseph Colacino, Q May Wang.   

Abstract

Eukaryotic initiation factor 4A (eIF4A) is an ATP-dependent RNA helicase and is homologous to the non-structural protein 3 (NS3) helicase domain encoded by hepatitis C virus (HCV). Reported here is the comparative characterization of human eIF4A and HCV NS3 helicase in an effort to better understand viral and cellular helicases of superfamily II and to assist in designing specific inhibitors against HCV infections. Both eIF4A and HCV NS3 helicase domain were expressed in bacterial cells as histidine-tagged proteins and purified to homogeneity. Purified eIF4A exhibited RNA-unwinding activity and acted on RNA or RNA/DNA but not DNA duplexes. In the absence of cellular cofactors, eIF4A operated unwinding in both the 3' to 5' and 5' to 3' directions, and was able to unwind blunt-ended RNA duplex, suggesting that bidirectionality is an intrinsic property of eIF4A. In contrast, HCV NS3 helicase showed unidirectional 3' to 5' unwinding of RNA and RNA/DNA, as well as of DNA duplexes. With respect to NTPase activity, eIF4A hydrolysed only ATP or dATP in the presence of RNAs, whereas HCV NS3 helicase could hydrolyse all ribo- and deoxyribo-NTPs in an RNA-independent manner. In parallel, only ATP or dATP could drive the unwinding activity of eIF4A whereas HCV NS3 could function with all eight standard NTPs and dNTPs. The observed differences in their substrate specificity may prove to be useful in designing specific inhibitors targeting HCV NS3 helicase but not human eIF4A.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11903057      PMCID: PMC1222461          DOI: 10.1042/0264-6021:3630147

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

1.  Further characterization of the helicase activity of eIF4A. Substrate specificity.

Authors:  G W Rogers; W F Lima; W C Merrick
Journal:  J Biol Chem       Date:  2001-01-16       Impact factor: 5.157

2.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

3.  RNA splicing. Alive with DEAD proteins.

Authors:  D A Wassarman; J A Steitz
Journal:  Nature       Date:  1991-02-07       Impact factor: 49.962

4.  Bidirectional RNA helicase activity of eucaryotic translation initiation factors 4A and 4F.

Authors:  F Rozen; I Edery; K Meerovitch; T E Dever; W C Merrick; N Sonenberg
Journal:  Mol Cell Biol       Date:  1990-03       Impact factor: 4.272

5.  The ATP-dependent interaction of eukaryotic initiation factors with mRNA.

Authors:  R D Abramson; T E Dever; T G Lawson; B K Ray; R E Thach; W C Merrick
Journal:  J Biol Chem       Date:  1987-03-15       Impact factor: 5.157

6.  Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase.

Authors:  N Yao; P Reichert; S S Taremi; W W Prosise; P C Weber
Journal:  Structure       Date:  1999-11-15       Impact factor: 5.006

Review 7.  Helicase, a target for novel inhibitors of hepatitis C virus.

Authors:  N Yao; P C Weber
Journal:  Antivir Ther       Date:  1998

8.  RNA-stimulated ATPase activity of eukaryotic initiation factors.

Authors:  J A Grifo; R D Abramson; C A Satler; W C Merrick
Journal:  J Biol Chem       Date:  1984-07-10       Impact factor: 5.157

9.  Two related superfamilies of putative helicases involved in replication, recombination, repair and expression of DNA and RNA genomes.

Authors:  A E Gorbalenya; E V Koonin; A P Donchenko; V M Blinov
Journal:  Nucleic Acids Res       Date:  1989-06-26       Impact factor: 16.971

Review 10.  Candidate targets for hepatitis C virus-specific antiviral therapy.

Authors:  R Bartenschlager
Journal:  Intervirology       Date:  1997       Impact factor: 1.763

View more
  10 in total

1.  The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently.

Authors:  David N Frick; Ryan S Rypma; Angela M I Lam; Baohua Gu
Journal:  J Biol Chem       Date:  2003-10-29       Impact factor: 5.157

2.  Single strand binding proteins increase the processivity of DNA unwinding by the hepatitis C virus helicase.

Authors:  Vaishnavi Rajagopal; Smita S Patel
Journal:  J Mol Biol       Date:  2007-11-01       Impact factor: 5.469

3.  A novel domain within the DEAD-box protein DP103 is essential for transcriptional repression and helicase activity.

Authors:  Xiaomei Yan; Jean-François Mouillet; Qinglin Ou; Yoel Sadovsky
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

4.  Second-site suppression of RNase E essentiality by mutation of the deaD RNA helicase in Escherichia coli.

Authors:  Masaru Tamura; Johan A Kers; Stanley N Cohen
Journal:  J Bacteriol       Date:  2012-02-10       Impact factor: 3.490

Review 5.  Helicases as antiviral drug targets.

Authors:  David N Frick
Journal:  Drug News Perspect       Date:  2003 Jul-Aug

6.  Two novel conserved motifs in the hepatitis C virus NS3 protein critical for helicase action.

Authors:  Angela M I Lam; David Keeney; David N Frick
Journal:  J Biol Chem       Date:  2003-08-27       Impact factor: 5.157

7.  Enhanced nucleic acid binding to ATP-bound hepatitis C virus NS3 helicase at low pH activates RNA unwinding.

Authors:  Angela M I Lam; Ryan S Rypma; David N Frick
Journal:  Nucleic Acids Res       Date:  2004-08-02       Impact factor: 16.971

8.  Hepatitis C virus NS3 ATPases/helicases from different genotypes exhibit variations in enzymatic properties.

Authors:  Angela M I Lam; David Keeney; Patrick Q Eckert; David N Frick
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  Transcriptional analysis of avian embryonic tissues following infection with avian infectious bronchitis virus.

Authors:  Arshud Dar; Shirin Munir; Satya Vishwanathan; Anju Manuja; Philip Griebel; Suresh Tikoo; Hugh Townsend; Andrew Potter; Vivek Kapur; Lorne A Babiuk
Journal:  Virus Res       Date:  2005-06       Impact factor: 3.303

10.  Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase.

Authors:  Sungjin Lee; Kee Dong Yoon; Myungeun Lee; Yoojin Cho; Gahee Choi; Hongje Jang; BeomSeok Kim; Da-Hee Jung; Jin-Gyo Oh; Geon-Woo Kim; Jong-Won Oh; Yong-Joo Jeong; Ho Jeong Kwon; Soo Kyung Bae; Dal-Hee Min; Marc P Windisch; Tae-Hwe Heo; Choongho Lee
Journal:  Br J Pharmacol       Date:  2015-11-25       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.